Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“The possibility that MTC can be driven/co‐driven by a MET mutation has potential management implications, since the tyrosine‐kinase inhibitor cabozantinib—approved for treating advanced MTCs—is a specific MET inhibitor.”
“ Mitomycin C and its methyl congener, porfiromycin, 2.2 × 10 −4 M and 5.7 × 10 −4 M, respectively, inhibited the incorporation of derivatives of 3 H-adenine and 3 H-uracil into RNA and DNA by approximately 50%.”